deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT02519842

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Subjects Receiving Emetogenic Chemotherapy

Sponsor: Merck Sharp & Dohme LLC

Conditions Chemotherapy-induced Nausea and Vomiting
Interventions 5-HT3 antagonist Dexamethasone Fosaprepitant Ondansetron Placebo for fosaprepitant
Updated 14 times since 2017 Last updated: Feb 28, 2019 Started: Sep 14, 2015 Primary completion: Feb 24, 2017 Completion: Feb 24, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

A PHASE3 clinical study on Chemotherapy-induced Nausea and Vomiting, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 14 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Aug 2017 · 5 months · monthly snapshot~Aug 2017 – ~Mar 2018 · 7 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Nov 2020 · 19 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Dec 2021 — Jun 2022 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

▶ Show 9 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE3

  2. Apr 2019 — Nov 2020 [monthly]

    Terminated PHASE3

  3. Jun 2018 — Apr 2019 [monthly]

    Terminated PHASE3

  4. May 2018 — Jun 2018 [monthly]

    Terminated PHASE3

  5. Mar 2018 — May 2018 [monthly]

    Terminated PHASE3

  6. Aug 2017 — Mar 2018 [monthly]

    Terminated PHASE3

  7. Mar 2017 — Aug 2017 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  8. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.